Gwyneth Paltrow Discusses New Weight-Loss Drug with Expert
In a recent episode of her podcast, Gwyneth Paltrow talked with neuroscientist Dr. Andrew Huberman about a new medication called retatrutide. This drug is part of a newer class known as GLP-1 therapies, which help regulate appetite and metabolism.
GLP-1 receptor agonists have gained popularity in talks about improving health and longevity, but they can also come with side effects. Dr. Huberman highlighted that traditional weight-loss drugs often reduced hunger but led to rapid weight loss, which sometimes meant losing muscle instead of just fat.
Understanding Retatrutide
Dr. Huberman explained that retatrutide is different. It’s a “triple agonist,” meaning it targets three receptors in the body related to blood sugar, appetite, and metabolism. This includes activating hormones such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon, along with the glucagon-like peptide-1 (GLP-1).
The new drug promises a gentler approach to weight loss. According to Dr. Huberman, retatrutide has a lower chance of causing side effects while allowing people to potentially lose about 30% of their body weight over a year.
Safety Concerns and Advice
However, retatrutide is still in clinical trials and is only available to those taking part in these studies. Dr. Huberman warned listeners about the risks of buying this drug from unregulated online sources, where quality can be questionable. He emphasized that impurities could lead to health issues.
Paltrow agreed, likening the current excitement around peptide therapies to the supplement boom of the 1990s, which lacked proper regulations. Both she and Dr. Huberman advised anyone considering these treatments to work closely with healthcare professionals.
Conclusion
As retatrutide continues its journey through clinical trials, experts stress that safety should come first. This medication could provide a new avenue for weight loss, but it’s essential to rely on verified sources and medical guidance as the situation develops.
